At 5.9% CAGR, Middle East & Africa Infusion Devices Market is Speculated to be Worth US$ 720.81 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the Middle East & Africa infusion devices market was valued at US$ 457.09 million in 2023 and is expected to reach US$ 720.81 million by 2031, registering a CAGR of 5.9% from 2023 to 2031. Increasing prevalence of cancer and growing geriatric population are among the critical factors attributed to driving the Middle East & Africa infusion devices market growth.

According to the National Cancer Institute, breast, lung and bronchus, colorectal, and prostate cancer account for almost 50% of all new cancer cases in the US. Colorectal, pancreatic, lung and bronchus, and breast cancers are responsible for ∼50% of all deaths. The incidence of cancer is rising globally. As per the WHO, in 2022, there were 19,976,499 cancer cases and 9,743,832 deaths due to cancer

The WHO has also estimated that the number of cancer cases is expected to reach 32.6 million by 2045.

Global Incidence of Cancer, 2022

Source: Cancer incidence and mortality data, WHO.

The globally increasing prevalence of cancer creates a burden on healthcare systems by bolstering the demand for chemotherapy, immunotherapy, and targeted therapy. Infusion devices are commonly used for delivering these treatments. Chemotherapy drugs are prescribed to be given slowly to reduce side effects, as they are highly toxic. Chemotherapies can also be taken orally. Other types of cancer therapies, such as immunotherapies and targeted therapies, use monoclonal antibodies. Infusion therapy is majorly required for administering treatment with monoclonal antibodies. These drugs are used to treat cancers and other conditions, such as autoimmune diseases. Infusions can be administered at a clinic or home. Thus, the increasing prevalence of cancer boosts the growth of the infusion devices market.

On the contrary, frequent product recalls of infusion devices hamper the growth of Middle East & Africa infusion devices market

By product type, the Middle East & Africa infusion devices market is segmented into infusion pumps and infusion sets. The infusion pumps held 75.2% share of Middle East & Africa infusion devices market share in 2023, amassing US$ 343.50 million. It is projected to garner US$ 548.95 million by 2031 to register 6.0% CAGR during 2023–2031.

In terms of infusion pumps, the market is segmented into volumetric pumps, syringe pumps, insulin pumps, patient control analgesia (PCA) pumps, enteral pumps, implantable pumps, and elastomeric pumps. The volumetric pumps segment held 29.0% share of Middle East & Africa infusion devices market share in 2023, amassing US$ 99.63 million. It is projected to garner US$ 154.30 million by 2031 to register 5.6% CAGR during 2023–2031.

By infusion sets, the Middle East & Africa infusion devices market is bifurcated into vented infusion sets and non-vented infusion sets. The vented infusion sets held 61.2% share of Middle East & Africa infusion devices market share in 2023, amassing US$ 69.47 million. It is projected to garner US$ 107.51 million by 2031 to register 5.6% CAGR during 2023–2031.

By application, the Middle East & Africa infusion devices market is segmented into diabetes, oncology, pain management, hematology, pediatrics, gastroenterology, and others. The diabetes held a 37.5% share of Middle East & Africa infusion devices market share in 2023, amassing US$ 171.53 million. It is projected to garner US$ 281.38 million by 2031 to register 6.4% CAGR during 2023–2031.

By end user, the Middle East & Africa infusion devices market is segmented into hospitals and specialty clinics, homecare settings, ambulatory surgical centers, and others. The hospitals and specialty clinics held 53.8% share of Middle East & Africa infusion devices market share in 2023, amassing US$ 245.84 million. It is projected to garner US$ 385.47 million by 2031 to register 5.8% CAGR during 2023–2031.

Based on country, the Middle East & Africa infusion devices market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 40.1% share of Middle East & Africa infusion devices market in 2023. It was assessed at US$ 183.34 million in 2023 and is likely to hit US$ 284.81 million by 2031, registering a CAGR of 5.7% during 2023–2031.

Key players operating in the infusion devices market are B Braun SE, Baxter International Inc, Becton Dickinson and Co, BPL Medical Technologies Pvt Ltd, CODAN US Corp, Eitan Medical Ltd, Elimedical Inc, Fresenius Kabi AG, ICU Medical Inc, KD Scientific Inc, Medtronic Plc, Moog Inc, Nipro Corp, Polymedicure, Tandem Diabetes Care Inc, Terumo Corp, Zimed Healthcare Ltd, and among others.

• In May-2024: Moog Inc. received US FDA 510(k) clearance for CURLIN 8000 Ambulatory Infusion System. This premium infusion platform was developed specifically for use in home infusion settings. The CURLIN 8000 combines a reliable and robust design with a simple, intuitive user interface designed for easy navigation by both clinical and non-clinical users. The CURLIN 8000 also integrates seamlessly with CURLIN RxManager, a completely new medication safety software developed to complement existing home infusion workflows.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com